Product/Composition:- | Insulin Glargine (Lantus) injectable |
---|---|
Strength:- | U-100, U-300 |
Form:- | Vials/pens |
Reference Brands:- | Lantus, Basaglar, Toujeo(US); Lantus, Toujeo(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Insulin Glargine (Lantus) provides a steady, long-lasting release of insulin, mimicking natural basal insulin to regulate blood sugar levels throughout the day. Its benefits include consistent glucose control, reduced risk of hypoglycemia, and improved insulin adherence, making it effective for managing both type 1 and type 2 diabetes.
nsulin Glargine (Lantus) is a long-acting basal insulin approved in the EU and US for managing diabetes. In the EU, it is regulated by the EMA, with Sanofi’s Lantus and Toujeo holding approved dossiers demonstrating safety and efficacy. In the US, the FDA approved Lantus and biosimilars like Basaglar, based on comprehensive clinical data and biosimilarity studies. Both regions require detailed dossiers and ongoing pharmacovigilance for post-marketing surveillance. For expert support with regulatory dossiers and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory services.